Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
TARS submitted a Form 144 notice reporting an intended sale of 3,125 shares of Common Stock tied to restricted stock vesting on 03/16/2026, with a listed dollar amount of $216,920.94. The filing also records a prior sale of 8,366 shares on 03/04/2026 by Seshadri Neervannan with a listed dollar amount of $641,421.22. The broker listed is Fidelity Brokerage Services LLC (address shown) and the trading venue is NASDAQ.
TARS filed a Form 144 notice for the sale of 4,029 shares of Common Stock. The filing lists the sale tied to a restricted stock vesting event dated 03/16/2026. The excerpt also shows a prior disposition of 15,565 shares by Dianne C. Whitfield on 01/02/2026.
This Form 144 is a routine Section 144 notice of proposed resale; the filing lists the broker as Fidelity Brokerage Services LLC and identifies the transaction as related to compensation vesting.
Tarsus Pharmaceuticals filed a Section 144 notice regarding the sale of 12,500 shares of Common Stock. The notice lists the sale filing on 03/16/2026 and records prior sales on 12/15/2025 by related holders with reported dollar amounts. The filing references a 01/10/2017 stock option exercise for 12,500 shares.
Wahl Bryan reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals General Counsel Bryan Wahl reported equity awards on March 5, 2026. He was granted stock options for 27,310 shares, with 25% vesting on March 5, 2027 and the remainder monthly over three years, and 17,161 restricted stock units vesting in four equal annual installments from March 15, 2027 to March 15, 2030, all subject to continuous service.
Tarsus Pharmaceuticals, Inc. reported that officer Jeffrey S. Farrow received equity awards consisting of a stock option for 30,724 shares and 19,306 restricted stock units, both granted at an exercise price of $0.0000 per share.
According to the grant terms, 25% of the option vests on March 5, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service. The 19,306 RSUs vest in four equal annual installments on March 15 of each of 2027, 2028, 2029, and 2030, also subject to ongoing service.